Our study, through sequencing and immunohistochemical analysis, showed that NSCLC with COPD exhibited down-regulation of HHLA2 expression in the tumor immune microenvironment, particularly in tumor cells. The gene discussed is HHLA2; the disease is non-small cell lung carcinoma.